European Neuropsychopharmacology
Volume 20, Issue 5 , Pages 310-316 , May 2010

Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST)

  • Wolfgang Gaebel

      Affiliations

    • Department of Psychiatry and Psychotherapy, Heinrich-Heine-University Düsseldorf, Rhineland State Clinics Düsseldorf, Germany
    • Corresponding Author InformationCorresponding author. Department of Psychiatry and Psychotherapy, Heinrich-Heine-University Düsseldorf, Rhineland State Clinics Düsseldorf, Bergische Landstraße 2, D-40629 Düsseldorf, Germany. Tel.: +49 211 922 2000; fax: +49 211 922 2020.
    • ,
  • Mathias Riesbeck

      Affiliations

    • Department of Psychiatry and Psychotherapy, Heinrich-Heine-University Düsseldorf, Rhineland State Clinics Düsseldorf, Germany
    • ,
  • Martina von Wilmsdorff

      Affiliations

    • Department of Psychiatry and Psychotherapy, Heinrich-Heine-University Düsseldorf, Rhineland State Clinics Düsseldorf, Germany
    • ,
  • Tom Burns

      Affiliations

    • Department of Psychiatry, University of Oxford, UK
    • ,
  • Eske M. Derks

      Affiliations

    • Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, The Netherlands
    • ,
  • René S. Kahn

      Affiliations

    • Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, The Netherlands
    • ,
  • Wulf Rössler

      Affiliations

    • Psychiatric University Hospital Zurich, Switzerland
    • ,
  • W. Wolfgang Fleischhacker

      Affiliations

    • Department of Biological Psychiatry, Medical University Innsbruck, Austria
    • ,
  • for the EUFEST Study Group

Received 3 December 2009 ,Revised 14 January 2010 ,Accepted 3 February 2010.

References 

  1. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 1990;3:247–251
  2. De Haan L, van Amelsvoort T, Dingemans P, Linszen D. Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; a prospective five year follow-up. Pharmacopsychiatry. 2007;40:264–268
  3. Dolder CR, Lacro JP, Warren KA, Golshan S, Perkins DO, Jeste DV. Brief evaluation of medication influences and beliefs: development and testing of a brief scale for medication adherence. J. Clin. Psychopharmacol. 2004;24:404–409
  4. Fleischhacker WW, Keet IP, Kahn RS. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophr. Res. 2005;78:147–156
  5. Gerlach J, Korsgaard S, Clemmesen P, et al. The St Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr. Scand. 1993;87:244–252
  6. Guy W. Clinical Global Impressions (CGI) Scale. In: ECDEU Assessment Manual for Psychopharmacology, revised. Washington, DC: US Dept Health, Education, and Welfare; 1976;p. 218–222
  7. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol. Med. 1983;13:177–183
  8. Hogarty GE, Schooler NR, Baker RW. Efficacy versus effectiveness. Psychiatr. Serv. 1997;48:1107
  9. Hsiao JK, Bartko JJ, Potter WZ. Diagnosing diagnosis. Arch. Gen. Psychiatry. 1989;46:664–667
  10. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085–1097
  11. Kampman O, Lehtinen K, Lassila V, et al. Attitudes towards neuroleptic treatment: reliability and validity of the Attitudes towards Neuroleptic Treatment (ANT) questionnaire. Schizophr. Res. 2000;45:223–234
  12. Kampman O, Laippala P, Väänänen J, Koivisto E, Kiviniemi P, Kilkku N, et al. Indicators of medication compliance in first-episode psychosis. Psychiatry Res. 2002;110:39–48
  13. Kay SR, Opler LA, Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) rating manual. Soc. Behav. Sci. Doc. 1986;17:28–29
  14. Kemp R, Hayward P, Applewhaite G, Everitt B, David A. Compliance therapy in psychotic patients: randomised controlled trial. BMJ. 1996;312:345–349
  15. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry. 2002;63:892–909
  16. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005;353:1209–1223
  17. McEvoy JP, Freter S, Everett G, Geller JL, Appelbaum P, Apperson LJ, et al. Insight and the clinical outcome of schizophrenic patients. J. Nerv. Ment. Dis. 1989;177:48–51
  18. Miller R, Ream G, McCormack J, Gunduz-Bruce H, Sevy S, Robinson D. A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophr. Res. 2009;113:138–144
  19. Mutsatsa SH, Joyce EM, Hutton SB, Webb E, Gibbins H, Paul S, et al. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr. Scand. 2003;108:439–446
  20. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J. Clin. Psychiatry. 2002;63:1121–1128
  21. Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrhino F, et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr. Res. 2006;83:53–63
  22. Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA. Comparison of Atypicals in First Episode study group.Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J. Clin. Psychiatry. 2008;69:106–113
  23. Priebe S, Huxley P, Knight S, Evans S. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int. J. Soc. Psychiatry. 1999;45:7–12
  24. Rabinovitch M, Béchard-Evans L, Schmitz N, Joober R, Malla A. Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis. Can. J. Psychiatry. 2009;54:28–35
  25. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr. Res. 2002;57:209–219
  26. Sackett DL, Haynes RB. The architecture of diagnostic research. BMJ. 2002;324:539–541
  27. Scandinavian Society of Psychopharmacology Committee of Clinical Investigations (UKU). The UKU Side Effect Rating Scale: scale for the registration of unwanted effects of psychotropics. Acta Psychiatr. Scand. 1987;76(334, suppl):81–94
  28. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry. 1998;59(suppl 20):22–33
  29. van der Gaag M, Hoffman T, Remijsen M, Hijman R, de Haan L, van Meijel B, et al. The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophr. Res. 2006;85:280–287
  30. Verdoux H, Lengronne J, Liraud F, Gonzales B, Assens F, Abalan F, et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr. Scand. 2000;102:203–210
  31. Weiden PJ. Understanding and addressing adherence issues in schizophrenia: from theory to practice. J. Clin. Psychiatry. 2007;68(Suppl 14):14–19
  32. Weiden P, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz-Lennon M, et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr. Bull. 1994;20:297–310

PII: S0924-977X(10)00020-9

doi: 10.1016/j.euroneuro.2010.02.001

European Neuropsychopharmacology
Volume 20, Issue 5 , Pages 310-316 , May 2010

Article Tools

* Image Usage & Resolution